VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Cue Biopharma, Inc. (CUE) Total Return Calculator with Dividends Reinvested

Cue Biopharma, Inc.

Popular:

The total return for Cue Biopharma, Inc. (CUE) stock is +50.96% over the past 12 months. So far it's up 235.77% this year. The 5-year total return is -89.61%, meaning $10,000 invested in CUE stock 5 years ago would be worth $1,039 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in CUE 1 year ago, it would be worth $14,742 today — you'd have gained $4,742.

With Dividends Reinvested$14,742+47.42%

Price Only (No DRIP)$14,742+47.42%

Period2025-05-07 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in CUE

1Y$15,096+$5,096 (+51.0%)51.0% CAGR

3Y$2,307-$7,693 (-76.9%)-38.7% CAGR

5Y$1,039-$8,961 (-89.6%)-36.4% CAGR

10Y$974-$9,026 (-90.3%)-20.8% CAGR

15Y$974-$9,026 (-90.3%)-14.4% CAGR

20Y$974-$9,026 (-90.3%)-11.0% CAGR

30Y$974-$9,026 (-90.3%)-7.5% CAGR

Cue Biopharma, Inc. did not pay dividends during this period. Total return = price return.

Loading CUE total return...

As of 2026-05-07

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	+235.77%	—	+235.77%	—	$33,577
1Y	+50.96%	50.96%	+50.96%	—	$15,096
3Y	-76.93%	-38.67%	-76.93%	—	$2,307
5Y	-89.61%	-36.42%	-89.61%	—	$1,039
10Y	-90.26%	-20.78%	-90.26%	—	$974
15Y	-90.26%	-14.38%	-90.26%	—	$974
20Y	-90.26%	-10.99%	-90.26%	—	$974
30Y	-90.26%	-7.47%	-90.26%	—	$974

Risk & Highlights

Best Year+207.66%2019

Worst Year-76.79%2022

Max Drawdown-98.63%2025-10-09 → 2026-01-24 · Recovered 2026-05-01

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-16.88%	-16.88%	—	+0.41%	-17.3pp
2025	-72.02%	-72.02%	—	+16.64%	-88.7pp
2024	-60.79%	-60.79%	—	+24.00%	-84.8pp
2023	-0.75%	-0.75%	—	+24.81%	-25.6pp
2022	-76.79%	-76.79%	—	-19.95%	-56.8pp

CUE outperformed the S&P 500 by 19.63pp over the past year (+50.96% vs +31.32%).

Loading summary...

CUE Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
CUECue Biopharma, Inc.	$89M	+539.9%	+235.8%	+51.0%	—	-76.9%	-89.6%	-90.3%
IMVTImmunovant, Inc.	$5.8B	+15.2%	+10.7%	+107.2%	—	+48.4%	+73.9%	+188.1%
AGIOAgios Pharmaceuticals, Inc.	$1.6B	-22.5%	-0.7%	-4.7%	—	+6.2%	-51.0%	-38.1%
KYMRKymera Therapeutics, Inc.	$7.0B	+1.2%	+18.6%	+201.9%	—	+211.0%	+110.5%	+159.4%
RCUSArcus Biosciences, Inc.	$2.6B	+16.9%	+11.6%	+220.2%	—	+31.0%	-13.7%	+52.9%
TGTXTG Therapeutics, Inc.	$6.7B	+24.6%	+43.3%	+20.4%	—	+26.8%	+5.3%	+425.9%
NKTRNektar Therapeutics	$1.7B	+13.9%	+96.0%	+783.6%	—	+636.7%	-69.4%	-57.6%
AGENAgenus Inc.	$137M	+3.2%	+20.4%	+31.0%	—	-87.8%	-93.1%	-93.5%
FATEFate Therapeutics, Inc.	$264M	+92.4%	+131.3%	+139.1%	—	-58.0%	-97.0%	+33.9%
ALKSAlkermes plc	$5.9B	+3.6%	+25.0%	+16.3%	—	+14.3%	+60.5%	-7.7%
XNCRXencor, Inc.	$954M	+4.6%	-12.8%	+53.8%	—	-52.4%	-67.2%	+14.8%

Compare:CUE vs IMVT CUE vs AGIO CUE vs KYMR CUE vs IMVT vs AGIO

About CUE Dividend Returns

Cue Biopharma, Inc. (CUE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CUE over the past year?

Cue Biopharma, Inc. (CUE) delivered a return of 50.96% over the past year. Since CUE does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in CUE be worth today?

A $10,000 investment in Cue Biopharma, Inc. one year ago would be worth $15,096 today, representing a gain of $5,096.

Q3Does CUE pay dividends?

Cue Biopharma, Inc. (CUE) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For CUE, the total return equals the price-only return.

Q4Did CUE beat the S&P 500?

Yes, Cue Biopharma, Inc. (CUE) outperformed the S&P 500 by 19.63 percentage points over the past year. CUE delivered a total return of 50.96%, compared to the S&P 500's 31.32%. This 19.63pp alpha means investors in CUE earned more than a passive S&P 500 index fund.

Q5What is CUE's worst drawdown?

Cue Biopharma, Inc. (CUE) experienced a maximum drawdown of -98.63% over the past year, declining from its peak on 2025-10-09 to its trough on 2026-01-24. The stock recovered to its prior peak by 2026-05-01. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CUE's long-term total return over 10, 20, or 30 years?

Here are Cue Biopharma, Inc. (CUE)'s long-term returns with dividends reinvested. Over 10 years, the total return is -90.3% (-20.8% CAGR) — $10,000 would have grown to $974. Over 20 years: -90.3% total return (-11.0% CAGR) — $10,000 → $974. Over 30 years: -90.3% total return (-7.5% CAGR) — $10,000 → $974. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CUE's best and worst year?

Cue Biopharma, Inc.'s best calendar year was 2019 with a total return of 207.7%. Its worst year was 2022 with a total return of -76.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 284.4 percentage points.